shr7390
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02968485)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mek inhibitor
- shr7390
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04676607 | Phase 2 | Dec 31, 2020 | Nanjing University |
| NCT04355858 | Phase 2 | May 1, 2020 | Fudan University |
| NCT03182673 | Phase 1 | Jun 1, 2017 | Hengrui Therapeutics, Inc., Sun Yat-Sen University |
| NCT02968485 | Phase 1 | Nov 1, 2016 | Hengrui Therapeutics, Inc., Sun Yat-Sen University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2016 |
| Sun Yat-Sen University | Academic/Hospital | 2 | 0 | 1 | 2016 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Nanjing University | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1